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Cell therapies derived from pluripotent stem cells are entering the preclinical and early clinical development
phase, but eventual translation faces many challenges. We describe a new approach by California to form
global public-private ‘‘disease team’’ partnerships to enable new clinical opportunities to be evaluated in
the complex regulatory environment.There are three key elements that must be
present to ensure the clinical translation of
candidate stem cell therapies. The first
two are obvious. There needs to be
adequate funding, and the therapies
need to be shown to be safe and effi-
cacious in accordance with regulatory
requirements. Third, and perhaps less
obvious, is in order to accelerate and
perhaps even succeed in demonstrating
safety and efficacy of these novel thera-
pies, researchers need to work in multi-
disciplinary, collaborative teams (U.S.
Department of Health and Human
Services, 2005).
The opportunity for stem cell science to
lead to therapeutic benefit is increasing as
evidenced by rapid advances and repro-
ducible results in so many parts of the
field from self-renewal and differentiation
to reprogramming pluripotentiality. There
are also challenges to realizing this oppor-
tunity. The business climate is presently
difficult, but it seems to be particularly
challenging for therapies originating from
pluripotent stem cells or genetically
manipulated adult stem cells. Venture
capital is increasingly risk-averse and
intolerant of waiting for long-term pay-
outs. Product regulatory bodies are acting
with caution, and insurers and healthcare
payers have yet to determine whether
health-care reform will allow them to
benefit from regenerative therapies that
are likely to require many years to accrue
sufficient savings to cover upfront costs.
Sustained funding will be critical
because the complex nature of the
delivery and monitoring of stem cell treat-
ments will result in an extended time
frame for development of many therapies.
Candidate small molecule and protein
therapeutics arising from stem cell re-search would be expected to reach the
clinic more quickly than pluripotential
stem cell treatments or even genetically
modified adult cells. Yet, with the field
promising to significantly alter healthcare
by delivering not just incremental
improvements but potentially cures, this
is an area that warrants investment and,
even in these difficult economic times,
public financial support.
With most funding sources pressuring
research to increase speed to the market
at the same time the Food and Drug
Administration (FDA) and other regulators
are showing caution with some new
avenues to therapy, industry publications
and conferences have started to discuss
the theory that the best way to increase
speed to market without increasing risk
is via industry-industry collaboration and
cooperation to solve the common preclin-
ical chalenges in the precompetitive
space (Brainloop, Inc., 2010; Cambridge
Health Institute, 2010). We postulate that
while this aspect of collaboration can
help, a broader, more effective way to
accelerate the path from research bench
to clinic is to foster academic-industry
collaborations that are structured in
a manner that is more focused than these
relationships have been in the past.
Academic stem cell biologists and those
clinicians who will be responsible for
testing these treatments can answer
questions that are blocking a particular
path to the clinic and may be able to
take advantage of more favorable
licensing and Material Transfer Agree-
ments (MTAs) offered to academia.
A discussion on risk involving regulators,
industry and academic team members,
patient advocates, and clinicians who
will be involved in delivery of the candi-Cell Stem Cdate therapy may be more productive in
looking at new measures of risk. Also,
since existing cell-based therapies,
largely from bone marrow, have generally
relied on academic-based clinical trials
and early roll-out, creating those partner-
ships that include clinical staff at the
beginning can cut steps and time to
a marketable product.
A test case of this hypothesis is
now underway. In October 2009, the
California Institute for Regenerative Medi-
cine (CIRM) awarded 14 Disease Team
Awards (CIRM, 2009), averaging over
U.S. $16 million each, and involved
some level of academic-industry partner-
ships to achieve the team goal of filing an
Investigational New Drug (IND) applica-
tion within 4 years to begin a clinical trial.
Four of the five awards for pluripotent-
derived therapies have industry participa-
tion, as do three of the five genetically
manipulated adult stem cell therapies.
Two of the three targeting cancer stem
cells have industry participants. In these
first awards, the grants were awarded
based on scientific merit and the potential
to achieve an IND filing. Hence, several
grants targeted the same disease. Given
the probability of success for any of the
awards is far from assured, CIRMdecided
not to restrict the awards programmati-
cally on this occasion.
Incentives for Translational
Research
As Dr. Susan Desmond-Hellmann, Chan-
cellor of UCSF and former President of
Product Development at Genentech,
stated at CIRM’s recent grantee confer-
ence, ‘‘what matters to patients is not
that these therapies get into a clinic, but
rather that they ultimately get approvedell 6, June 4, 2010 ª2010 Elsevier Inc. 513
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into clinical trials that matters; it’s getting
commercial approval for use in all patients
that could benefit. This requires funding of
the complete program from preclinical
translational studies to the safety and
proof of concept of benefit to patients,
commonly referred to as Phase I and
IIA/B clinical trials. There is very little fund-
ing available from investment financing or
pharmaceutical company support for this
component of the development chain.
It is necessary for private foundations
and public funding initiatives, such as
NIH’s expenditures on Clinical and Trans-
lation Science Centers, to fill the void left
by the virtual exit of angel funders (inves-
tors interested for simply programmatic
reasons) and venture capital from the
translational phases of stem cell research.
In the present difficult economic environ-
ment, it is challenging to persuade
government to contribute to funding
medical research despite the acknowl-
edged economic return of such invest-
ments because the benefits are long
term and budget shortfalls are acute
(Murphy and Topel, 2003; Health
Economics Research Group, 2008). The
long-term benefits for the economy and
for health require funding that is reliably
sustained for decades. This enables the
discovery process to mature and the
translational phase to support proof of
concept. Few public agencies adequately
support the translation phase, and even
those that do require multiple grant appli-
cation rounds to enable a new product,
such as stem cells, to reach a mature
stage attractive for private investment.
CIRM has decided to invest signifi-
cantly in preclinical and clinical research
with grants of up to U.S. $25 million for
pluripotent-derived stem cell candidate
clinical trials, up to U.S. $20 million for
each ‘‘Disease Team’’ research award
and up to U.S. $6 million each for ‘‘Early
Translational’’ research awards. These
awards are large enough to support
multiple phases of preclinical-clinical
development through a single grant appli-
cation and have been supplemented with
additional funding by collaborative fund-
ing partners in other nations and, in
some instances, further leveraged by
funds from the grantee.
The size of the grants available and the
potential to collaborate within California
and with overseas and interstate re-514 Cell Stem Cell 6, June 4, 2010 ª2010 Elssearchers has dramatically incentivized
the research community. There are
a very large number of applications
submitted to CIRM in response to calls
for applications, many with merit for
support.
Global Collaborations Accelerate
Research Benefits
Team research is effective in achieving
high impact developments because of
its speed of producing innovative high
quality data. This is true on a national
scale and an international scale, but there
are relatively few funding bodies that
support international collaborations
between multiple public and private
teams. The European Framework Pro-
gramme and NIH have such collaborative
initiatives, but they are limited in number
and in the level of funding available for
translational research. While some coun-
tries have some private-public funding
mechanisms, they are still relatively rare
and don’t provide comprehensive funding
for the full translational process, particu-
larly for stem cell research. One partial
exception is seen in Spain, in the form of
the Andalusian Initiative for Advanced
Therapies (Cuende and Izeta, 2010, this
issue). Klein and Trounson have argued
that state or international bond funded
initiatives for such purposes can be
a very effective approach to stimulate
these arrangements with little direct influ-
ence on public debt repayments before
substantial economic returns are gener-
ated (Klein and Trounson, 2010). They
argue returns to California on the bond
sales are likely to be substantial as debt
repayments are offset for 5 years in the
capital raising, and taxation benefits
accrue as buildings are erected and
academic and biotechnology compo-
nents expand. Clinical trials have already
been initiated with potentially large
savings on the state’s healthcare budget
expected.
CIRM has taken a very proactive role in
creating international collaborative agree-
ments to cofund stem cell research.
These agreements enable scientists to
jointly submit research team applications
for review by CIRM’s international review
panels (excludes Californian reviewers)
and the collaborating national or state
review panels if necessary. The agree-
ments include the State of Victoria,
Australia, the Canadian Cancer Stemevier Inc.Cell Consortium, the UK Medical Re-
search Council, the Japanese Science
and Technology (JST) organization, the
Chinese Ministry of Science and Tech-
nology, Spanish Ministry of Science and
Innovation, German Ministry of Education
andResearch, and theU.S. State ofMary-
land and the New York Stem Cell Founda-
tion.
Globalizing collaborations provides
opportunities for different communities
to participate in the development of
a new area of research and to ensure
that the priorities of these communities
are included in determining the direction
of the research. Consequently the
emphasis on cancer stem cells is driven
by both Californian and Canadian
researchers as a priority for their commu-
nities. Certain diseases that may domi-
nate in one community may be less
frequent in another but collaborative
research tends to be inclusive of these
needs. For example, the need for afford-
able cures for diseases such as HIV/
AIDS and malaria becomes evident
when global health priorities are consid-
ered.
Regulatory Approval: Drugs
and Biologics versus Cell Therapies
While CIRM’s funding of the translational
phases of the research pipeline will
provide the critical financial support
needed to meet the first condition laid
out above for success in this field, the
second element, proving safety and effi-
cacy, will be more challenging. Unlike for
biologics and small molecules, the regu-
latory pathway for stem cell-derived ther-
apeutics is not well defined and, hence,
not well understood. While the biologic
and small molecule industries benefit
from a well-defined regulatory pathway
and commonly accepted best practices
for preclinical safety testing, product
characterization, and measures of purity
and potency, the same cannot be said
for product development for the stem
cell industry. Certainly, there are
a number of autologous stem cell thera-
pies in clinical trial as well as some allo-
genic adult cell therapies, but pluripotent
and genetically manipulated stem cell
therapies are experiencing significant
delays in entering into the clinic (Plagnol
et al., 2009). While it may be argued
that companies need to address signifi-
cant concerns of the regulators, the
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tional data and approval to proceed
makes survival particularly difficult for
any corporate entity with limited financial
flexibility (McKernan et al., 2010, this
issue). While the FDA is not insensitive
to the situation, many unknowns remain
in this new field that can delay approvals,
despite the best intentions of all parties.
The US federal government has taken
steps to address the issue. The FDA is in
active discussion with industry, in part
through the Regenerative Medicine Con-
sortium, which was convened by CIRM
and has a mix of industry and academic
participants. FDA Commissioner Mar-
garet Hamburg’s emphasis in regulatory
sciencemay ultimately providemore tools
and regulatory certainty to the field. Like-
wise, NIH has declared its intention to
work with the FDA as well.
There are concerns that the relative
ease of obtaining regulatory approval for
clinical studies for transient cell therapies,
such as those based on autologous bone
marrow implantations for a wide variety of
disorders without solid scientific ratio-
nale, may be counterproductive for regu-
latory support of regenerative therapies
involving pluripotent stem cell derivatives.
Others see these as a logical order for the
relative risk versus benefit.
Developing a Symbiotic Team
Approach
In the absence of well-defined regulatory
requirements for the development and
approval of pluripotential and genetically
manipulated stem cell therapeutics, it is
necessary to have sufficient innovative
expertise on the team to address the
concerns of regulators. The knowledge
base for new developments in stem cell
biology generally resides in the academic
research community and in biotechnology
companies with a substantial research
capacity or those well connected to
academic research groups. The
academic community is, however, gener-
ally less well prepared for the highly regu-
lated aspects of product development,
particularly those relating to toxicological
testing, consistency, and source of
product as required for cGMP (current
Good Manufacturing Practices) manu-
facturing, etc. Academic scientists are,
in many instances, less familiar with the
timeline and milestone demands of
industry, where delays in product devel-opment are very costly, not only to the
funder but potentially to the patient. There
is clearly a potential symbiotic relation-
ship between academic research talent
and the know-how of the biotechnology
industry. In fact, it is difficult for one to
make major advances without the other
in the present relative absence of signifi-
cant venture capital.
The depth of research resources in the
university sector and the considerable
infrastructure there is of immense value
to biotechnology companies that have
limited capital. The companies, in turn,
can keep academic scientists focused
on the critical developments needed for
regulatory filing. Hence, merging the
resources provided by companies and
academic research institutions can create
the ideal team.
CIRM has implemented an active team
management approach for its multidisci-
plinary Disease Teams. The approach is
based on best practices following discus-
sion with individuals whose expertise and
relevant experience derives from
academia, the biotechnology and phar-
maceutical industries, and from private
foundations (CIRM, 2007).
Challenges to translational research
teams include maintaining focus, en-
suring that the scope of the research con-
ducted best addresses the project goal,
and maintaining good communication
among team members and with funders.
For Disease Team projects, each team is
required to have a project team leader(s)
and a project manager with development
experience to ensure team direction,
focus, energy, and communication. Prior
to the start of funding, to further facilitate
successful project outcomes, each
team, together with CIRM, develops
mutually agreed upon timelines for key
project activities and determines mile-
stones that reflect critical measures of
project progress and go/no go decision
points. These, in conjunction with an
activity based budget, help teams to
refine project plans to ensure that all
necessary research is conducted, and
that the time and funding allowed for the
conduct of the research activities are
sufficient and reasonable.
The response of the Disease Team
investigators to the new funding format
opportunity has been exceptional, given
that academics are rarely organized in
such a targeted and highly focusedCell Stem Cmanner. These academic-industry part-
nerships could provide ongoing benefit
in future steps as well. It is anticipated
that, like bone marrow and organ trans-
plantation, many new cell therapies are
likely to be delivered in tertiary clinical
settings that will involve academic and
community clinicians and networked
stem cell clinics that may be partnered
with companies supplying specific
reagents and cell products.
Public-Private Partnerships for
Translation Established by CIRM
Funding
In the area of human embryonic stem cells
(hESCs), the studies on dry macular
degeneration at the University of
Southern California, University of Califor-
nia (UC) Santa Barbara, and University
College London are further enhanced
through collaboration with the company
Geron and the Center for Applied Tech-
nology Development (CATD) at City of
Hope, which serves as a national
academic biologics manufacturing re-
source. Geron and CATD provide cell
banks, cGMP manufacturing, and exper-
tise for regulatory requirements. A study
on ESCs derivatives for treatment of
stroke at Stanford University has a collab-
oration with Progenitor Cell Therapy,
a company that provides the expertise in
product and assay development and
cGMP manufacturing for the therapeutic
candidate. This team is also working
with SRI whose expertise in toxicological
testing and their successful record in
medical product development are major
assets. Progenitor Cell Therapy will also
be participating in the development and
manufacture of neural stem cells on
behalf of a team at UC San Francisco in
support of their efforts to leverage the
homing ability of these cells to deliver
drugs to treat glioblastoma. The team
from UC San Diego and the Salk Institute
are working with Life Technologies Inc. for
the scale-up, differentiation, and purifica-
tion of ESCs to astrocyte precursors and
cGMP manufacturing for treatment of
Amyotrophic Lateral Sclerosis (ALS). For
diabetes, the company ViaCyte Inc. has
several associations with academia,
including a critical collaboration on
immune modulation with UC San Fran-
cisco.
For genetically modified adult stem
cells, the team at the City of Hope thatell 6, June 4, 2010 ª2010 Elsevier Inc. 515
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HIV/AIDS is using Sangamo Biosciences’
novel zinc-finger nuclease (ZFN) tech-
nology to disrupt the gene CCR5 in hema-
topoietic stem cells (HSCs), which
encodes a critical HIV coreceptor in blood
cells. The team at UC Los Angeles is
mimicking a naturally occurring mutation
in CCR5 by transducing the patient’s
HSCs using a shRNA . They are partnered
with City of Hope’s CATD and with Calim-
mune Inc., who provide expertise in
preclinical development and product
commercialization. According to the Prin-
cipal investigator Dr. Chen, ‘‘traditionally,
research, drug development, and clinical
medicine were three virtually separate en-
deavors.CIRM created a funding mech-
anism that breaks down the barriers to
this critical interaction.’’ (Atchison, 2010).
Connecting to the End User
While organizations like CIRM are unable
to maintain financial support beyond
Phase II studies of proof of concept for
human efficacy, it can provide the data
that make the project more attractive for
Phase III partnerships involving venture
funding and major pharmaceutical
company support. However, with the
costs of clinical trials spiraling out of
control with estimates now approaching
U.S. $4 billion per drug (Munos, 2009), it
seems unlikely that the present model is516 Cell Stem Cell 6, June 4, 2010 ª2010 Elssustainable, particularly for smaller
market diseases. It is apparent that
government may need to coinvest and to
persuade the health insurance companies
to also join in supporting biotech and
pharma in the clinical trials. Government
and health insurance companies are
beneficiaries of cures and improvement
in the quality of life of patients with serious
diseases. With the increasing number of
clinical trials proposed for cell therapies,
there is an urgent need to address this
issue.
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